Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + Olaparib in Recurrent Ovarian Cancer
NCT04999605Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in ovarian cancer, sponsored by Akeso, Inc. Primary endpoints: Number of subjects with adverse events and Objective Response Rate. Started Jun 2021; status: terminated.
02
Drugs
ivonescimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04999605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999605.